ライフサイエンスコーパス: tricuspid valve

1 ramyocardial traversal but did not cross the tricuspid valve.

2 of great arteries and Ebstein anomaly of the tricuspid valve.

3 be strongly influenced by the status of the tricuspid valve.

4 atrioventricular valve, and 97 had a single tricuspid valve.

5 that extends posteriorly to the plane of the tricuspid valve.

6 es, good operator technique, and a competent tricuspid valve.

7 by MRSA was evaluated for replacement of the tricuspid valve.

8 red with age- and size-matched controls with tricuspid valves.

9 many currently untreated patients with leaky tricuspid valves.

10 n and morphogenesis of the mature mitral and tricuspid valves.

11 n pulmonary valves, 22 mitral valves, and 21 tricuspid valves.

12 with bicuspid aortic valves than those with tricuspid valves.

13 ater gives rise to the septum and mitral and tricuspid valves.

14 ram abnormalities extended from perivalvular tricuspid valves (5 patients), pulmonic valves (6 patien

15 of tricuspid atresia that includes an absent tricuspid valve, a large ASD, a VSD, an elongated left v

16 almost exclusively into the right atrium and tricuspid valve; a small amount that was refluxed from t

17 Ebstein's anomaly and other tricuspid valve abnormalities were also present.

18 lmonary atresia, six with severe obstructive tricuspid valve abnormalities, five with severe tetralog

19 gher clinical success rates according to the Tricuspid Valve Academic Research Consortium at 30 days

20 Intraprocedural success according to Tricuspid Valve Academic Research Consortium criteria wa

21 A second Tricuspid Valve Academic Research Consortium document wi

22 in the superior and inferior caval veins and tricuspid valve (adjusted r = 0.28-0.55; all P < .01), p

23 rmined by factors in the right ventricle and tricuspid valve and not the timing of or the type of sur

24 More flow dependence was associated with tricuspid valves and the morphologic features characteri

25 ables, and specific details on aortic/mitral/tricuspid valves and their specific interventions.

26 septal defects, Ebstein malformation of the tricuspid valve, and perimembranous and muscular ventric

27 cardiographic dataset at baseline revealed a tricuspid valve annular area of 14.1 cm(2), and effectiv

28 Most rings currently used for tricuspid valve annuloplasty are formed in a single plan

29 Only 98 (8%) patients underwent tricuspid valve annuloplasty during follow-up.

30 ly Feasibility of the Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) Also Known a

31 The SCOUT (Percutaneous Tricuspid Valve Annuloplasty System for Symptomatic Chro

32 ve surgery, and discuss the emerging role of tricuspid valve annuloplasty with left ventricular assis

33 increasingly supports the use of corrective tricuspid valve annuloplasty, and the growing consensus

34 We aimed to examine the 3D geometry of the tricuspid valve annulus (TVA) in patients with functiona

35 95% confidence interval, 3.5-21.0; P<0.001), tricuspid valve annulus diameter z-score (odds ratio, 1.

36 ices of RV size and function, neo-aortic and tricuspid valve annulus dimensions and function, and aor

37 mined by atrial activation mapping along the tricuspid valve annulus during tachycardia and was furth

38 Tricuspid valve annulus was measured in a 4-chamber view

39 inferior vena cava, and from the RCA to the tricuspid valve annulus were measured.

40 ining the lateral tunnel suture line and the tricuspid valve annulus.

41 ns have been few, however, in the therapy of tricuspid valve anomalies, especially Ebstein's malforma

42 f correcting pathological alterations of the tricuspid valve apparatus may lead to more robust repair

43 munication, smaller aortic root size, larger tricuspid valve area z-score, and larger left ventricula

44 ve regurgitation (<5% at each time), indexed tricuspid valve area, and >/=moderate tricuspid valve re

45 he optimal ICD configuration in a paediatric tricuspid valve atresia patient; (3) establish whether t

46 onconduit positions such as in bioprosthetic tricuspid valves, branch pulmonary arteries, aortic and

47 ator leads on the incidence of bioprosthetic tricuspid valve (BTV) regurgitation compared with BTV pa

48 Damage to the tricuspid valve by PPM or ICD leads may result in severe

49 block, peri-hepatic bleeding, and rupture of tricuspid valve chordae tendineae.

50 nction were quantified as RA inflow with the tricuspid valve closed versus open, respectively.

51 CAD), and those requiring concomitant mitral/tricuspid valve (CMTV) or concomitant ascending aorta re

52 tant TVI is safe and results in better early tricuspid valve competence than isolated PVR.

53 affected by associated intracardiac defects, tricuspid valve competence, and systemic right ventricul

54 lantation, for 20 (3.0%) total patients with tricuspid valve complications.

55 racterized by the congenital agenesis of the tricuspid valve connecting the right atrium to the right

56 e damage (Stage 2), pulmonary vasculature or tricuspid valve damage (Stage 3), or right ventricular d

57 ve damage; stage 3, pulmonary vasculature or tricuspid valve damage; and stage 4, right ventricular d

58 ter z score was lower (P<0.001) and the mean tricuspid valve diameter z score was higher in fetuses w

59 isease who may also concurrently suffer from tricuspid valve disease and atrial fibrillation.

60 eart failure, pulmonary hypertension, mitral/tricuspid valve disease and/or combined surgeries.

61 nscatheter interventions to treat mitral and tricuspid valve disease are becoming increasingly availa

62 The assessment and management of tricuspid valve disease have evolved substantially durin

63 Patients with aortic/mitral/tricuspid valve disease or root/ascending aorta >40 mm w

64 tients who have mitral valve with or without tricuspid valve disease with a significant history of at

65 atients with evidence of moderate or greater tricuspid valve disease, left-sided valve disease, pulmo

66 ole of cross-sectional imaging in mitral and tricuspid valve disease, primarily valvular regurgitatio

67 attention has been given to the treatment of tricuspid valve disease.

68 to be suitable for treatment of all cases of tricuspid valve disease.

69 integrated into the evaluation of mitral and tricuspid valve disease.

70 mitral valve prolapse (OR 2.725; P < .0001), tricuspid valve disorders (OR 2.142; P < .0001), cardiac

71 LP therapy is associated with an increase in tricuspid valve dysfunction through 12 months of follow-

72 Ebstein anomaly and tricuspid valve dysplasia are rare congenital tricuspid

73 Fetuses diagnosed with Ebstein anomaly and tricuspid valve dysplasia from 2005 to 2011 were include

74 y series of fetuses with Ebstein anomaly and tricuspid valve dysplasia, perinatal mortality remained

75 ed recipient also had pulmonary stenosis and tricuspid valve dysplasia.

76 ic data who underwent isolated transcatheter tricuspid valve edge-to-edge repair for significant tric

77 In patients undergoing transcatheter tricuspid valve edge-to-edge repair, invasive hemodynami

78 ion of patients considered for transcatheter tricuspid valve edge-to-edge repair.

79 al in 4] and bicuspid in 458); 417 (45%) had tricuspid valves (either absent or minimal commissural f

80 ar-old woman who had received a diagnosis of tricuspid valve endocarditis caused by MRSA was evaluate

81 is an option for intravenous drug users with tricuspid valve endocarditis.

82 atrial pressure (RAP) score (comprising the tricuspid valve, foramen ovale, and ductus venosus Doppl

83 ts: 35 with functional TR and 40 with normal tricuspid valve function (referent group).

84 of patients who will not show improvement in tricuspid valve function after this operation.

85 TR, comparing them with patients with normal tricuspid valve function and relating annular geometric

86 ost patients show significant improvement in tricuspid valve function.

87 was not significantly different whether the tricuspid valve had been repaired (4 of 9 [44%]) or surg

88 Optimal aortic and tricuspid valve imaging will depend on further technolog

89 st 1 A4C video with color Doppler across the tricuspid valve in 2410 of 2462 studies with a sensitivi

90 ients (aortic valve in 5, mitral valve in 9, tricuspid valve in 4, catheter in 2 and pacemaker in 2,

91 Fibrosis involved the tricuspid valve in 5 patients, and 1 had perforation of

92 lip device was successfully implanted in the tricuspid valve in 97% of the cases.

93 epatic shunts stent that migrated across the tricuspid valve in a patient with Child-Pugh category C

94 ion was achieved between 2 and 7 mm from the tricuspid valve in imaging planes containing the AV musc

95 describe right atrial activation around the tricuspid valve in the left anterior oblique view.

96 ed normal intracardiac connections, with the tricuspid valve in the normal position and normal size o

97 re also have a morphological RV and delicate tricuspid valve in the systemic circulation.

98 ) category, with impairment of aortic and/or tricuspid valves in addition to mitral valve damage.

99 cular valve (SAVV) intervention (morphologic tricuspid valve) in congenitally corrected transposition

100 er aortic and pulmonary valve prostheses for tricuspid valve-in-valve implantation (TVIV) within dysf

101 tion of the LP was associated with increased tricuspid valve incompetence (odds ratio, 5.20; P=0.03).

102 5% CI, 30.2%-44.9%]) patients, predominantly tricuspid valve infection (43/177 [24.3%]), with associa

103 IDU-IE patients more frequently had tricuspid valve infection, Staphylococcus infection, and

104 ffective, and safe in treating patients with tricuspid valve infective endocarditis refractory to med

105 Of the 29 patients with tricuspid valve infective endocarditis who underwent per

106 In patients with tricuspid valve infective endocarditis, percutaneous deb

107 of the systemic venous portion of the medial tricuspid valve/inferior vena cava isthmus was attempted

108 Among patients with available data, tricuspid valve injury was documented in 11 (1.7%), and

109 year later the patient developed mitral and tricuspid valve insufficiency and subsequently underwent

110 t as a result of chamber enlargement, severe tricuspid valve insufficiency resulted in a detectable r

111 se included intraventricular septum defects, tricuspid valve insufficiency, and diaphragm defects, wh

112 ages of the mitral valve (MV), aortic valve, tricuspid valve, interatrial septum, and left atrial app

113 sought to evaluate the impact of concomitant tricuspid valve intervention (TVI) on post-operative TR,

114 t selection in future trials to determine if tricuspid valve intervention improves outcomes in this h

115 7.6% versus 29.3%; P<0.0001), driven by more tricuspid valve intervention in control patients who cro

116 ause mortality, tricuspid valve surgery, and tricuspid valve intervention through 2 years was signifi

117 spid regurgitation and RVD/PH, transcatheter tricuspid valve intervention was associated with high pr

118 evice-based therapies, such as transcatheter tricuspid valve intervention, gene therapy in patients w

119 y hypertension (PH) undergoing transcatheter tricuspid valve intervention.

120 from any cause (14.8% vs. 12.5%), postindex tricuspid-valve intervention (3.2% vs. 0.6%), and improv

121 Transcatheter tricuspid valve interventions (TTVI) are promising, but

122 Surgical mortality for isolated tricuspid valve interventions remains higher than for an

123 t is not known whether the properties of the tricuspid valve isthmus differ from those of the remaind

124 m and superior vena cava, crista terminalis, tricuspid valve isthmus, coronary sinus orifice, membran

125 There was a perforation of the tricuspid valve leaflet by the PPM or ICD lead in 7 pati

126 to the ventricular phenotype, in A-STR, the tricuspid valve leaflet tethering is typically trivial.

127 urred in 4 patients, lead impingement of the tricuspid valve leaflets occurred in 16 patients, and le

128 there is an insufficient adaptive growth of tricuspid valve leaflets that become unable to cover the

129 icular heart failure in sheep that developed tricuspid valve leakage.

130 .6 million Americans suffer from significant tricuspid valve leakage.

131 pothesis, we set out to demonstrate that the tricuspid valve maladapts in disease.

132 lenge this paradigm and hypothesize that the tricuspid valve maladapts in those patients rendering th

133 Canine tricuspid valve malformation (CTVM) maps to canine chrom

134 ricuspid valve dysplasia are rare congenital tricuspid valve malformations associated with high perin

135 Patients with Ebstein's anomaly of the tricuspid valve may have exercise limitation that improv

136 because timely surgery on the pulmonary and tricuspid valves may preserve RV size and function.

137 ricular (RV) pacing are well-known causes of tricuspid valve, mitral valve, and cardiac dysfunction.

138 efine echocardiographic views for evaluating tricuspid valve morphology and function, and discuss ima

139 Tricuspid valve morphology, degree of tricuspid valve re

140 Porcine tricuspid valves (n=16) were studied in an in vitro righ

141 ed in 16 patients, and lead adherence to the tricuspid valve occurred in 14 patients.

142 lead in 7 patients, lead entanglement in the tricuspid valve occurred in 4 patients, lead impingement

143 tricuspid regurgitation (r=0.692; P=0.009), tricuspid valve offset (r=0.583; P=0.004), and tricuspid

144 All patients underwent successful tricuspid valve operation (22 tricuspid valve replacemen

145 wed the records of 41 patients who underwent tricuspid valve operation for severe tricuspid regurgita

146 gh this seemed to be predominantly driven by tricuspid valve or pulmonary artery vasculature damage (

147 itral valve or left atrial damage), Stage 3 (tricuspid valve or pulmonary artery vasculature damage),

148 applied to disease affecting the mitral and tricuspid valves or their annuli.

149 multivalve surgery that did not include the tricuspid valve (OR, 2.1; 95% CI, 1.3 to 3.3), preoperat

150 .7) and multivalve surgery that included the tricuspid valve (OR, 3.7; 95% CI, 2.3 to 6.1) were the s

151 observed in TAD, apical displacement of the tricuspid valve, or other features compared with the gro

152 artery bypass grafting or aortic, mitral or tricuspid valve, or thoracic aorta surgery between Octob

153 ry artery bypass grafting or aortic, mitral, tricuspid valve, or thoracic aorta surgical procedures b

154 ation (STR) is the most frequent etiology of tricuspid valve pathology in Western countries.

155 propose a new staging system for functional tricuspid valve pathology using 3 parameters that may mo

156 In comparison with patients with tricuspid valves, patients with bicuspid AV were younger

157 sessment in guiding transcatheter mitral and tricuspid valve percutaneous interventions.

158 the AVN toward the coronary sinus along the tricuspid valve (posterior nodal extension, PNE).

159 y pressure of more than 60 mm Hg, a previous tricuspid valve procedure, or a cardiovascular implantab

160 itral valve procedures (TMVP), transcatheter tricuspid valve procedures (TTVP), as well as procedural

161 ) as independent predictors while concurrent tricuspid valve procedures (TVP) were not predictors.

162 th safety and performance of a transcatheter tricuspid valve reconstruction system in the treatment o

163 Patients with a tricuspid-valve regurgitant jet velocity >/=3.2 m/s (3.6

164 The positive predictive value for the tricuspid-valve regurgitant jet velocity >/=3.2 m/s thre

165 ndexed tricuspid valve area, and >/=moderate tricuspid valve regurgitation (<20% at each time).

166 AF) is considered a risk factor for isolated tricuspid valve regurgitation (TR) in the absence of oth

167 Late echocardiographic failure (3 to 4+ tricuspid valve regurgitation [TR]) after TV surgery was

168 lyzes the factors responsible for changes in tricuspid valve regurgitation after pulmonary endarterec

169 /59; 14%) were found to have a minimum of 2+ tricuspid valve regurgitation before hemi-Fontan or Font

170 We report a series of patients with severe tricuspid valve regurgitation due to a permanent pacemak

171 etermine the incidence of moderate to severe tricuspid valve regurgitation in children with hypoplast

172 The changes in tricuspid valve regurgitation in the LP group were simil

173 Moderate to severe tricuspid valve regurgitation is a common finding in pat

174 this study was to explore the full range of tricuspid valve regurgitation velocity (TRV) at rest and

175 Tricuspid valve regurgitation was graded as being more s

176 Tricuspid valve morphology, degree of tricuspid valve regurgitation, and right ventricular fun

177 during hybrid palliation, moderate to severe tricuspid valve regurgitation, and smaller ascending aor

178 Tricuspid valve regurgitation, SV, HR and CO were signif

179 pressure, and more severe RV enlargement and tricuspid valve regurgitation.

180 lasty (n=3), recoarctation repair (n=2), and tricuspid valve repair (n=1).

181 and 213 patients who received transcatheter tricuspid valve repair (TTVR).

182 al surgical strategies to improve results of tricuspid valve repair and close surveillance after surg

183 after excluding the 3 patients who underwent tricuspid valve repair as part of their HF procedure.

184 rgery, and concomitant procedures other than tricuspid valve repair at the time of LVAD.

185 Transcatheter tricuspid valve repair could become an effective treatme

186 the first-in-human successful transcatheter tricuspid valve repair for severe tricuspid regurgitatio

187 ir of prosthetic mitral valve leak in 2; and tricuspid valve repair in 5.

188 The operation includes tricuspid valve repair or replacement and frequent conco

189 antable cardiac defibrillator, and mitral or tricuspid valve repair or replacement, can be (partially

190 s such as cardiac resynchronization therapy, tricuspid valve repair or replacement, pulmonary artery

191 nalysed in all patients who had an attempted tricuspid valve repair procedure upon femoral vein punct

192 gating safety and performance of the TriClip Tricuspid Valve Repair System in patients with moderate

193 scular Outcomes In Patients Treated With the Tricuspid Valve Repair System Pivotal [TRILUMINATE Pivot

194 scular Outcomes in Patients Treated With the Tricuspid Valve Repair System Pivotal) found that transc

195 scular Outcomes In Patients Treated With the Tricuspid Valve Repair System Pivotal) is an internation

196 scular Outcomes In Patients Treated With the Tricuspid Valve Repair System Pivotal) is the first rand

197 scular Outcomes in Patients Treated with the Tricuspid Valve Repair System Pivotal), tricuspid transc

198 scular Outcomes In Patients Treated With the Tricuspid Valve Repair System Pivotal; NCT03904147).

199 TriClip, a minimally invasive transcatheter tricuspid valve repair system, for reducing tricuspid re

200 ge-to-edge repair technique with the TriClip tricuspid valve repair system.

201 emi-Fontan or Fontan operation who underwent tricuspid valve repair were included.

202 Patients undergoing tricuspid valve repair were older (mean age 59.2 years v

203 al role in guiding the procedure (mitral and tricuspid valve repair, left atrial appendage closure, a

204 ciency and subsequently underwent mitral and tricuspid valve repair, pulmonary valve replacement, and

205 mechanistic and therapeutic implications for tricuspid valve repair.

206 patients undergoing transcatheter mitral and tricuspid valve repair.

207 to benefit from leaflet augmentation during tricuspid valve repair.

208 09 per 5 mg/dL increase; P<0.0001), previous tricuspid valve repair/replacement (ORs, 2.01-10.09; P<0

209 o inform a decision about whether to perform tricuspid-valve repair during mitral-valve surgery in pa

210 All had tricuspid valve replacement (159 bioprostheses, 36 mecha

211 Orthotopic transcatheter tricuspid valve replacement (TTVR) devices have been sho

212 n (TR) treated with the EVOQUE transcatheter tricuspid valve replacement (TTVR) system plus medical t

213 m valve-related outcomes after transcatheter tricuspid valve replacement (TTVR), including valve func

214 life), which may improve with transcatheter tricuspid valve replacement (TTVR).

215 Tricuspid valve replacement (TVR) with allograft mitral

216 Ninety-seven patients who underwent initial tricuspid valve replacement are included in the present

217 Tricuspid valve replacement for severe tricuspid regurgi

218 % men; age, 67.5+/-11.3 years) who underwent tricuspid valve replacement for severe tricuspid regurgi

219 Surgery included tricuspid valve replacement in all patients, pulmonary v

220 002) was reviewed to evaluate the results of tricuspid valve replacement in children <6 years of age.

221 increased mortality and worse outcome after tricuspid valve replacement in patients with severe tric

222 Early outcomes after tricuspid valve replacement in young children are ill de

223 6% bioprosthetic valve; P=0.01) CONCLUSIONS: Tricuspid valve replacement in young children is associa

224 Surgical options other than tricuspid valve replacement such as transplantation may

225 re or greater TR 2:1 to TTVR with the EVOQUE tricuspid valve replacement system plus optimal medical

226 Age at tricuspid valve replacement was 2.9+/-1.7 years (mean+/-

227 ent successful tricuspid valve operation (22 tricuspid valve replacement), with one perioperative dea

228 TT-VIVR as a viable alternative to surgical tricuspid valve replacement, especially in high-risk pat

229 In 68 patients with isolated tricuspid valve replacement, the associations between sh

230 tality risk associated with reoperations for tricuspid valve replacement, these data suggest favorabl

231 a 2:1 ratio to undergo either transcatheter tricuspid-valve replacement and medical therapy (valve-r

232 ng outcomes after percutaneous transcatheter tricuspid-valve replacement are needed.

233 evere tricuspid regurgitation, transcatheter tricuspid-valve replacement was superior to medical ther

234 +/-0.4 versus 0.6+/-0.3, P<0.0001), a larger tricuspid valve ring diameter (P<0.0001), and prolonged

235 3 to 3.7]) increased risk of CAD, and to the tricuspid valve (RR, 5.5 [95% CI, 2.0 to 15.1]) and righ

236 tware aided delineation of the RV free wall, tricuspid valve, RV outflow tract, and apex on 3D echo v

237 Radiofrequency ablation at the tricuspid valve's insertion into the AV muscular septum

238 ocardiographic indices of RV, neoaortic, and tricuspid valve size and function at 14 months, pre-Font

239 Tricuspid valve stenosis was not documented in any of th

240 odel, KEi(EDV) E/A ratio and 4D flow derived tricuspid valve stroke volume demonstrated independent a

241 all-cause mortality (17.9% versus 17.1%) and tricuspid valve surgery (2.3% versus 4.3%) were similar

242 d conservatively, and 551 underwent isolated tricuspid valve surgery (200 repairs and 351 replacement

243 years; P < .001), were undergoing mitral or tricuspid valve surgery (51% vs 32%, P < .001), or had h

244 In the subset of patients who underwent tricuspid valve surgery (n = 344), a post-operative impr

245 ared between patients who underwent isolated tricuspid valve surgery (repair or replacement) and thos

246 ) had secondary TR, and 87 (33.2%) underwent tricuspid valve surgery after CMR.

247 ate of patients being referred for mitral or tricuspid valve surgery after previous cardiac surgery i

248 Rates of all-cause mortality or tricuspid valve surgery and HFH through 1 year were not

249 roperatively in 120 patients who underwent a tricuspid valve surgery and using TTE (A4C) in 66 health

250 ectomy for constrictive pericarditis without tricuspid valve surgery and with pre- and postoperative

251 Historically, isolated tricuspid valve surgery has been associated with high in

252 ry bypass grafting, and/or aortic, mitral or tricuspid valve surgery in Ontario, Canada, between 2008

253 Isolated tricuspid valve surgery is associated with high morbidit

254 RECENT FINDINGS: The rationale for offering tricuspid valve surgery is based upon an understanding o

255 based on anatomic complexity and history of tricuspid valve surgery or of subpulmonic obstruction.

256 Freedom from all-cause mortality and tricuspid valve surgery through 12 months was 90.6% and

257 The indications for tricuspid valve surgery to treat tricuspid regurgitation

258 failure symptoms of 2.03 (1.14-3.60), while tricuspid valve surgery was borderline protective with 0

259 Tricuspid valve surgery was necessary in 87 of the 89 pr

260 oracotomy approach for reoperative mitral or tricuspid valve surgery was used in 62 patients from Jan

261 t study, 371 Ebstein patients that underwent tricuspid valve surgery were divided into 3 groups: norm

262 Y (1217 conservatively managed, 551 isolated tricuspid valve surgery, and 645 transcatheter valve rep

263 s favoring a more aggressive approach toward tricuspid valve surgery, and discuss the emerging role o

264 Freedom from all-cause mortality, tricuspid valve surgery, and tricuspid valve interventio

265 with isolated severe TR, 171 (5%) underwent tricuspid valve surgery, including 143 (84%) repairs and

266 Finally, operative mortality for isolated tricuspid valve surgery, particularly re-operative surge

267 ion sequence, ejection fraction, concomitant tricuspid valve surgery, type of valve operation, concom

268 e RV dysfunction but not anatomy or need for tricuspid valve surgery.

269 y artery bypass grafting; aortic, mitral, or tricuspid valve surgery; ascending aorta surgery without

270 now include echocardiographic parameters of tricuspid valve tenting area, and associated right ventr

271 orm the transcatheter bicuspidization of the tricuspid valve, the Mitralign system was used to place

272 The TriValve (Transcatheter Tricuspid Valve Therapies) registry collected 472 patien

273 clinical trials for transcatheter mitral or tricuspid valve therapies, trial hospitals took care of

274 rthermore, novel surgical and interventional tricuspid valve treatment options are increasingly appli

275 Porcine tricuspid valve (TV) (n = 3) was extracted and incorpora

276 Tricuspid valve (TV) annuloplasty is recommended for fun

277 Measurements of the PV annulus, tricuspid valve (TV) annulus and main, right and left pu

278 ntation (TVIV) within dysfunctional surgical tricuspid valve (TV) bioprostheses has been described in

279 assess the remodeling potential of a tubular tricuspid valve (TV) bioprosthesis made of SIS-ECM by ev

280 Tricuspid valve (TV) disease has been relatively neglect

281 Severe tricuspid valve (TV) dysfunction may lead to surgical TV

282 le electronic device leads to interfere with tricuspid valve (TV) function has gained increasing reco

283 itation (TR), early results of transcatheter tricuspid valve (TV) intervention studies have shown sig

284 Severe isolated disease of the tricuspid valve (TV) is increasing and results in intrac

285 egurgitation (TR) with a structurally normal tricuspid valve (TV) may occur secondary to chronic atri

286 The durability of tricuspid valve (TV) repair by annuloplasty is limited.

287 enosis or regurgitation after prior surgical tricuspid valve (TV) replacement or repair.

288 cant tricuspid regurgitation (TR) or require tricuspid valve (TV) surgery in the medium term have det

289 diographic-guided treatment on outcome after tricuspid valve (TV) surgery is not well defined.

290 EDs) in patients with Ebstein anomaly during tricuspid valve (TV) surgery is unknown.

291 o moderate-severe TR by 6 mo and 1 underwent tricuspid valve (TV) surgery.

292 clustering approach, we defined atrial TR as tricuspid valve (TV) tenting height <=10 mm, midventricu

293 uspid valves, and in all 12 AR patients with tricuspid valves unassociated with the Marfan syndrome.

294 ciated defects, such as abnormalities of the tricuspid valve, ventricular septal defect, and pulmonar

295 The mean (SD) initial z-score for the tricuspid valve was -5.1 (+/-3.4), and a further 142 set

296 The tricuspid valve was affected in all 8 patients (73%), pu

297 valve was replaced in 33 cases (59) and the tricuspid valve was repaired/replaced in 10 (18).

298 The tricuspid valve was virtually ignored for a long time in

299 Native aortic and tricuspid valves were optimally visualized only in 18% a

300 alves (slope 0.21 cm2/100 ml per s) than for tricuspid valves with <10% commissural fusion (slope 0.3